tbuckley/cabot-search huggingface dataset:
P291Non-invasive in vivo human model of the involvement of human epidermal mitochondria in the early post-ischaemic preconditioning
Authors: G Sibrecht, J Nizinski, P Filberek, J Zielinski, K Kusy, T Krauze, J Piskorski, S Michalak, A Wykretowicz, P Guzik
Journal: Cardiovascular Research (2018)
Vaccine hesitancy in the French population in 2016, and its association with vaccine uptake and perceived vaccine risk–benefit balance
Authors: Dominique Rey, Lisa Fressard, Sébastien Cortaredona, Aurélie Bocquier, Arnaud Gautier, Patrick Peretti-Watel, Pierre Verger
Journal: Eurosurveillance (2018)

Background Vaccine hesitancy (VH) is prominent in France. Objectives: This study aimed to estimate the prevalence and socio-demographic correlates of VH in sub-groups of the French population and to investigate the association of VH with both vaccine uptake and perceived risk–benefit balance (RBB) for four vaccines. Methods : During the 2016 Health Barometer – a national cross-sectional telephone survey in a representative sample of the French population – parents of 1–15 year-old children, parents of 11–15 year-old girls and elderly people aged 65–75 years were asked about VH (using three questions adapted from the World Health Organization definition), vaccine uptake and perceived RBB for measles and hepatitis B (children’s parents), human papillomavirus (girls’ parents) and seasonal influenza (elderly people) vaccines. Results : A total of 3,938 parents including 959 girls' parents – and 2,418 elderly people were interviewed. VH prevalence estimates were 46% (95% confidence interval (CI): 44–48) among parents, 48% (95%CI: 45–51) among girls’ parents and 35% (95% CI: 33–36) among elderly people, with higher estimates associated with high education level, children’s age (10–15 years), and, for the elderly, poor perception of health status. VH was associated with uncertainty about and/or an unfavourable perception of vaccines’ RBB for the four vaccines and with lower self-reported vaccine uptake, except for human papillomavirus vaccine in girls. Results were confirmed by multivariable analysis. Conclusion : Further research is needed to study the association between VH and vaccine uptake for other vaccines, and to design and validate measurement tools to monitor VH over time.
Diagnostic performance and problem analysis of commercial tuberculosis antibody detection kits in China
Authors: Xue-Juan Bai, You-Rong Yang, Jian-Qin Liang, Hui-Ru An, Jie Wang, Yan-Bo Ling, Zhong-Yuan Wang, Xue-Qiong Wu
Journal: Military Medical Research (2018)

The diagnosis of bacterium-negative pulmonary tuberculosis (TB) and extra-pulmonary TB is challenging clinically. The detection of the anti-TB antibody has an important, auxiliary, clinical diagnostic value. Therefore, TB antibody detection kits should be screened and evaluated, and the reagents with the highest sensitivity and specificity should be chosen and used clinically.The diagnostic performance of 7 commercially available TB antibody detection kits (kits A, B, C, D, E, F and G) based on the gold immunoassay detection of immunoglobulin (Ig) G or IgM antibodies were simultaneously evaluated and compared in 62 TB cases and 56 non-TB cases in a laboratory. A retrospective analysis including 2549 cases was carried out to assess the clinical diagnosis values of bacteriological examinations and TB antibody tests (kits B and H used in the clinic).The sensitivities of TB antibody kits A, B, C, D, E, F and G in the sera from 62 TB patients were 50.0%, 83.9%, 38.7%, 9.7%, 48.4%, 69.4% and 79.0%, respectively; the sensitivities in the sera from 24 smear-negative TB patients were 29.2%, 79.2%, 29.2%, 12.5%, 29.2%, 54.2% and 79.2%, respectively; the specificities in the sera from 56 non-TB patients were 73.2%, 25.0%, 85.7%, 96.4%, 78.6%, 78.6% and 50.0%, respectively. Of the 2549 clinically diagnosed cases, there were 1752 pulmonary TB cases, 505 extra-pulmonary TB cases, 87 old pulmonary TB cases and 205 non-TB cases. The positive results for smear, culture, TB antibody kit B and kit H in pulmonary TB cases were 39.8% (543/1365), 48.6% (372/765), 45.8% (802/1752) and 25.2% (442/1752), respectively; the results in extra-pulmonary TB cases were 3.4% (6/178), 5.8% (4/69), 35.4% (179/505), and 11.3% (57/505), respectively; the results in old pulmonary TB cases were 0% (0/64), 0% (0/30), 32.2% (28/87), and 9.2% (8/87), respectively; and the results in non-TB cases were 0% (0/121), 0% (0/56), 21.5% (44/205), and 2.4% (5/205), respectively. Of 624 smear-positive and/or culture-positive pulmonary TB cases, the sensitivities of antibody test kits B and H were 53.0% and 36.4%, respectively. Of 901 smear-negative and/or culture-negative pulmonary TB cases, the sensitivities of antibody test kits B and H were 42.5% and 19.0%, respectively. The positive rate of antibody detection in the bacterium-positive pulmonary TB cases was significantly higher than that in the bacterium-negative pulmonary TB cases (P < 0.05).The colloidal gold-labeled TB antibody IgG detection assay is a simple, rapid and economical method that provides a better clinical auxiliary diagnosis value on TB, especially in smear-negative pulmonary TB and extra-pulmonary TB. The production, quality control, screening and evaluation of antibody detection kits are very important for its clinical application.
Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 (vol 161, pg 461, 2014)
Authors: JL Lennox, RJ Landovitz, HJ Ribaudo, I Ofotokun, LH Na, C Godfrey
Journal: Annals of Internal Medicine (2014)
Difference of gene mutational profile among viral- and non-viral HCC with or without prior HBV infection: Results of comprehensive deep sequencing analyses of cancer genes and HBV/AAV integration
Authors: F. Kawai-Kitahata, Y. Asahina, S. Kakinuma, M. Murakawa, S. Nitta, H. Nagata, S. Kaneko, E. Inoue, M. Miyoshi, T. Tsunoda, A. Sato, M. Nakagawa, Y. Itsui, S. Azuma, S. Tanaka, M. Tanabe, S. Maekawa, N. Enomoto, M. Watanabe
Journal: Journal of Hepatology (2018)
Virtual Consultations Through the Veterans Administration SCAN‐ECHO Project Improves Survival for Veterans With Liver Disease
Authors: Grace L. Su, Lisa Glass, Elliot B. Tapper, Tony Van, Akbar K. Waljee, Anne E. Sales
Journal: Hepatology (2018)

Access to specialty care has been associated with improved survival in patients with liver disease but universal access is not always feasible. Methods of care delivery using virtual modalities including the SCAN-ECHO (Specialty Access Network-Extension of Community Healthcare Outcome) program were implemented by the Veterans Health Administration (VHA) to address this need but limited data are available on patient outcomes. We sought to evaluate the efficacy of a SCAN-ECHO visit within the context of a regional cohort of patients with liver disease in the VHA (n = 62,237) following implementation in the Ann Arbor SCAN-ECHO Liver Clinic from June 1, 2011, to March 31, 2015. The effect of a SCAN-ECHO visit on all-cause mortality was compared with patients with no liver clinic visit. To adjust for the differences among patients who had a SCAN-ECHO visit versus those with no visit, propensity score matching was performed on condition factors that affect the likelihood of a SCAN-ECHO visit: demographics, geographic location, liver disease diagnosis, severity, and comorbidities. During the study period, 513 patients who had a liver SCAN-ECHO visit were found within the cohort. Patients who had completed a virtual SCAN-ECHO visit were more likely younger, rural, with more significant liver disease, and evidence for cirrhosis. Propensity-adjusted mortality rates using the Cox Proportional Hazard Model showed that a SCAN-ECHO visit was associated with a hazard ratio of 0.54 (95% confidence interval 0.36-0.81, P = 0.003) compared with no visit. Conclusion: Improved survival in patients using SCAN-ECHO suggests that this approach may be an effective method to improve access for selected patients with liver disease, particularly in rural and underserved populations where access to specialty care is limited.
Diagnosis and Treatment of Hidradenitis Suppurativa
Authors: Issra Rashed, James S. Welsh
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antibiotic‐Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant
Authors: Jasmohan S. Bajaj, Genta Kakiyama, Tor Savidge, Hajime Takei, Zain A. Kassam, Andrew Fagan, Edith A. Gavis, William M. Pandak, Hiroshi Nittono, Phillip B. Hylemon, Prapaporn Boonma, Anthony Haag, Douglas M. Heuman, Michael Fuchs, Binu John, Masoumeh Sikaroodi, Patrick M. Gillevet
Journal: Hepatology (2018)

Patients with cirrhosis are often exposed to antibiotics that can lead to resistance and fungal overgrowth. The role of fecal microbial transplant (FMT) in restoring gut microbial function is unclear in cirrhosis. In a Food and Drug Administration–monitored phase 1 clinical safety trial, patients with decompensated cirrhosis on standard therapies (lactulose and rifaximin) were randomized to standard‐of‐care (SOC, no antibiotics/FMT) or 5 days of broad‐spectrum antibiotics followed by FMT from a donor enriched in Lachnospiraceae and Ruminococcaceae. Microbial composition (diversity, family‐level relative abundances), function (fecal bile acid [BA] deconjugation, 7α‐dehydroxylation, short‐chain fatty acids [SCFAs]), and correlations between Lachnospiraceae, Ruminococcaceae, and clinical variables were analyzed at baseline, postantibiotics, and 15 days post‐FMT. FMT was well tolerated. Postantibiotics, there was a reduced microbial diversity and autochthonous taxa relative abundance. This was associated with an altered fecal SCFA and BA profile. Correlation linkage changes from beneficial at baseline to negative after antibiotics. All of these parameters became statistically similar post‐FMT to baseline levels. No changes were seen in the SOC group. Conclusion: In patients with advanced cirrhosis on lactulose and rifaximin, FMT restored antibiotic‐associated disruption in microbial diversity and function. (H epatology 2018; 00:000‐000).
The Wrong Frame of Mind
Authors: Joseph A. McBride, Alexander J. Lepak, Gurpreet Dhaliwal, Sanjay Saint, Nasia Safdar
Journal: New England Journal of Medicine (2018)

A 62-year-old woman with hypertension and depression presented to a urology clinic with a 15-month history of episodic dysuria, hematuria, and polyuria. She reported suprapubic discomfort but no flank pain, nausea, or early satiety.
Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy
Authors: Ariel Bier, Peter Berenstein, Noam Kronfeld, Daria Morgoulis, Amotz Ziv-Av, Hodaya Goldstein, Gila Kazimirsky, Simona Cazacu, Rinat Meir, Rachela Popovtzer, Amir Dori, Chaya Brodie
Journal: Biomaterials (2018)
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
Authors: Matthew J. Maurer, Hervé Ghesquières, Brian K. Link, Jean-Philippe Jais, Thomas M. Habermann, Carrie A. Thompson, Corinne Haioun, Cristine Allmer, Patrick B. Johnston, Richard Delarue, Ivana N. Micallef, Frederic Peyrade, David J. Inwards, Nicolas Ketterer, Umar Farooq, Olivier Fitoussi, William R. Macon, Thierry J. Molina, Sergei Syrbu, Andrew L. Feldman, Susan L. Slager, George J. Weiner, Stephen M. Ansell, James R. Cerhan, Gilles A. Salles, Thomas E. Witzig, Hervé Tilly, Grzegorz S. Nowakowski
Journal: Journal of Clinical Oncology (2018)

Purpose Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is concern that patients with clinically aggressive disease may not have enrolled in recent diffuse large B-cell lymphoma (DLBCL) trials due to the consent process and the inability to delay therapy for eligibility evaluation. We have examined the diagnosis-to-treatment interval (DTI) and its association with clinical factors and outcome in a clinic-based observational cohort of patients with DLBCL from the United States. Validation of results was performed in an independent, clinical trial-based cohort from Europe. Patients and Methods Patients were prospectively enrolled in the University of Iowa and Mayo Clinic Specialized Programs of Research Excellence Molecular Epidemiology Resource (MER; N = 986) or the Lymphoma Study Association (LYSA) LNH-2003 clinical trials program (N = 1,444). All patients received anthracycline-based immunochemotherapy at initial diagnosis. Associations of DTI with clinical factors and outcome were examined. Outcome was assessed using event-free survival at 24 months from diagnosis (EFS24). Results Median (range) DTI was 15 days (0 to 155 days in the MER and 23 days (0 to 215 days) in LYSA. Shorter DTI was strongly associated with adverse clinical factors, including elevated lactate dehydrogenase levels, poor performance status, B symptoms, and higher International Prognostic Index in both cohorts (all P &lt; .001). Longer DTI was associated with improved EFS24 in both the MER (per-week odds ratio, 0.80; 95% CI, 0.74 to .0.87) and LYSA (per-week odds ratio, 0.90; 95% CI, 0.86 to 0.94); association with EFS24 remained significant after adjustment for International Prognostic Index. Conclusion DTI is strongly associated with prognostic clinical factors and outcome in newly diagnosed DLBCL. DTI should be reported in all clinical trials of newly diagnosed DLBCL and future trials should take steps to avoid selection bias due to treatment delay.
Sofosbuvir + Glecaprevir/Pibrentasvir in patients with difficult to treat HCV infection. Final results of the French compassionate use
Authors: V.D. Ledinghen, V. Anne, U.-B. Jose, P. Lucia, H. Jean-Baptiste, S. Giovanna, M. Wassil, G.-P. Pageaux, F. Helene, L. Alric, C. Hezode
Journal: Journal of Hepatology (2018)
Dances With Denial: Have Medical Oncology Outpatients Conveyed Their End-of-Life Wishes and Do They Want To?
Authors: Amy Waller, Charles Douglas, Rob Sanson-Fisher, Nicholas Zdenkowski, Angela Pearce, Tiffany Evans, Justin Walsh
Journal: Journal of the National Comprehensive Cancer Network (2018)

Objectives: This study surveyed a sample of medical oncology outpatients to determine (1) the proportion who have already discussed and documented their end-of-life (EOL) wishes; (2) when and with whom they would prefer to convey their EOL wishes; (3) the EOL issues they would want to discuss; and (4) the association between perceived cancer status and advance care planning (ACP) participation. Methods: Adult medical oncology outpatients were approached in the waiting room of an Australian tertiary treatment center. Consenting participants completed a pen-and-paper survey assessing participation in ACP, preferences for conveying EOL wishes, timing of EOL discussions, and EOL issues they want to be asked about. Results: A total of 203 patients returned the survey (47% of eligible). EOL discussions occurred more frequently with support persons (47%) than with doctors (7%). Only 14% had recorded their wishes, and 45% had appointed an enduring guardian. Those who perceived their cancer as incurable were more likely to have participated in ACP. If facing EOL, patients indicated that they would want family involved in discussions (85%), to be able to write down EOL wishes (82%), and to appoint enduring guardians (91%). Many (45%) preferred the first discussion to happen when their disease became incurable. Slightly less than one-third thought discussions regarding EOL should be patient-initiated. Most agreed doctors should ask about preferred decision-making involvement (92%), how important it is that pain is managed well (95%), and how important it is to remain conscious (82%). Fewer (55%) wanted to be asked about the importance of care extending life. Conclusions: Many patients would like to have discussions regarding EOL care with their doctor and involve their support persons in this process. Only a small percentage of respondents had discussed EOL care with their doctors, recorded their wishes, or appointed an enduring guardian. The first step requires clinicians to ask whether an individual patient wishes to discuss EOL issues, in what format, and at what level of detail.
Hippocampal 5-HT Input Regulates Memory Formation and Schaffer Collateral Excitation
Authors: Catia M. Teixeira, Zev B. Rosen, Deepika Suri, Qian Sun, Marc Hersh, Derya Sargin, Iva Dincheva, Ashlea A. Morgan, Stephen Spivack, Anne C. Krok, Tessa Hirschfeld-Stoler, Evelyn K. Lambe, Steven A. Siegelbaum, Mark S. Ansorge
Journal: Neuron (2018)
Impact of surgical margin according to AFP ratebefore hepatectomy for hepatocellular carcinoma
Authors: Frédéric Marques, E. Boleslawski, O. Ciacio, D. Cherqui, M.-A. Allard, N. Golse, D. Castaing, René Adam, J.-M. Regimbeau, J.-Y. Mabrut, F.-R. Pruvot, D. Samuel, E. Vibert
Journal: Journal of Hepatology (2018)
Abstract 17229: Survival after Veno-arterial Extracorporeal Membrane Oxygenation Support is Dependent on Underlying Etiology of Cardiogenic Shock
Authors: Brett J Carroll, Stephen A McCullough, Ravi V Shah, Gregory D Lewis, Janice M Camuso, William D Carlson, Kimberly A Parks, Stephanie A Moore, Christopher H Newton-Cheh, Nitasha Sarswat, Tae H Song, Thomas E Macgillivray, Serguei Melnitchouk, Thoralf M Sundt, Marc J Semigran, Joshua N Baker, Jose P Garcia
Journal: Circulation (2014)

Introduction: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is an emerging therapy for refractory cardiogenic shock (CS); however, characteristics of patients most likely to benefit from this therapy remain to be determined. We hypothesized that the underlying etiology of CS and patient specific characteristics predict survival to discharge. Methods: We compared outcomes in patients supported with VA-ECMO for refractory CS resulting from (1) acute myocardial infarction (AMI; with or without revascularization); (2) acute pulmonary embolism (PE); (3) acute cardiomyopathy; (4) chronic cardiomyopathy; (5) post-cardiotomy; and (6) other etiologies of shock. Chi-square analysis was used to identify predictors of survival to discharge after VA-ECMO. Results: From 2009-2013, 102 patients were initiated on VA-ECMO for refractory CS. The average age was 52 ±15 (mean ± SD) years old with 71 (70%) males. Overall, 39 (38%) patients survived to discharge. In the cohort, 22 patients were post-cardiotomy and 5 (23%) of those survived to discharge. Of the 80 patients without prior cardiotomy, survival to discharge was 27% (8/30) after AMI, 64% (9/14) after PE, 75% (6/8) with acute cardiomyopathy, 50% (5/10) with chronic cardiomyopathy, and 39% (7/18) with other CS etiologies. Survivors were younger (45 ±13 vs 56 ±14, p = 0.0002) and none of the 24 patients over the age of 64 years old survived to discharge. There was a significant difference in survival when comparing etiologies of shock (p = 0.012 by Chi-square comparison among etiologies). There was no significant difference in survival by gender. Conclusions: Survival in patients with refractory CS requiring VA-ECMO may depend on age and underlying etiology of shock. Further research into predictors of survival after institution of VA-ECMO is warranted.
In Vitro Tissue‐Engineered Skeletal Muscle Models for Studying Muscle Physiology and Disease
Authors: Alastair Khodabukus, Neel Prabhu, Jason Wang, Nenad Bursac
Journal: Advanced Healthcare Materials (2018)

Healthy skeletal muscle possesses the extraordinary ability to regenerate in response to small-scale injuries; however, this self-repair capacity becomes overwhelmed with aging, genetic myopathies, and large muscle loss. The failure of small animal models to accurately replicate human muscle disease, injury and to predict clinically-relevant drug responses has driven the development of high fidelity in vitro skeletal muscle models. Herein, the progress made and challenges ahead in engineering biomimetic human skeletal muscle tissues that can recapitulate muscle development, genetic diseases, regeneration, and drug response is discussed. Bioengineering approaches used to improve engineered muscle structure and function as well as the functionality of satellite cells to allow modeling muscle regeneration in vitro are also highlighted. Next, a historical overview on the generation of skeletal muscle cells and tissues from human pluripotent stem cells, and a discussion on the potential of these approaches to model and treat genetic diseases such as Duchenne muscular dystrophy, is provided. Finally, the need to integrate multiorgan microphysiological systems to generate improved drug discovery technologies with the potential to complement or supersede current preclinical animal models of muscle disease is described.
P92Reduced myofilament calcium-sensitivity in diabetic human left ventricular cardiomyocytes
Authors: J C Baldi, G T Wilkins, R R Lamberts, G M Diffee
Journal: Cardiovascular Research (2018)

The multifactorial linear regression model (aR 2 ¼0.559, p<0.001) indicated Ns (B¼6.9460.92,b¼0.72; h<0.001) and mBP (B¼0.41760.057,b¼0.696; h¼0.001) as independent predictors of the NT plasma level in rats.Conclusions: 1) The blood pressure elevation in rats is accompanied by increased expression both of nNOS and iNOS, whereas the eNOS level remained unchanged.2) The changes stated above are accompanied by increased expression of mRNA of all NOS isoforms, including eNOS, which may be an evidence of the eNOS high demand in myocardium.3) Considering the progressive decrease of the nitrates concentration in myocardium homogenates and the simultaneous plasma nitrotyrosine level increase, which are correspond to the mean blood pressure elevation, all the stated above may be considered as development of changes in myocardium, which are identical to endothelial dysfunction, including eNOS uncoupling with the shift of its activity to peroxynitrite production despite of NO.